INTREPAD:萘普生延缓症状前阿尔茨海默病进展的随机试验
INTREPAD是一项为期2年的双盲药物预防试验,纳入195名有AD家族史且认知正常的老年人,随机接受萘普生钠220mg每日两次或安慰剂。主要结局为多模态复合症状前阿尔茨海默进展评分(APS)的变化率。结果显示萘普生组不良事件明显增多,且未显著减缓APS进展(治疗相关率比1.16,95%CI 0.64-1.96)。
要点
- 萘普生钠220mg每日两次未显著减缓症状前AD的APS进展。
- 萘普生治疗组不良事件明显多于安慰剂组。
- 该研究提供I级证据支持低剂量萘普生对认知正常者症状前AD进展无显著获益。
核心结论
- 在认知正常但有AD风险的老年人中,持续使用萘普生钠220mg每日两次增加不良健康事件频率,但不减少症状前AD的表观进展。
研究设计与样本
- INTREPAD为2年双盲药物预防试验,纳入195名有AD家族史且认知正常的老年人(平均年龄63岁),1:1随机接受萘普生钠220mg每日两次或安慰剂。
- 改良意向性分析纳入160名至第一次随访时仍在治疗中的参与者。
主要发现
- 萘普生治疗组不良事件明显增多。
- 合并治疗组APS每年增加0.102分(SE 0.014;p < 10-12),但变化率在治疗组间差异很小(0.019分/年)。
- 治疗相关率比为1.16(95%CI 0.64-1.96),提示萘普生未能将APS进展率降低超过36%。
- 次要分析显示对CSF、认知或神经感觉生物标志物指标无显著治疗效应。
关键数值与推荐
- 主要结局为多模态复合症状前阿尔茨海默进展评分(APS)的变化率。
- 治疗相关率比1.16(95%CI 0.64-1.96)。
- APS合并治疗组每年增加0.102分(SE 0.014;p < 10-12)。
临床怎么用
- 不支持对有AD家族史但认知正常的老年人使用低剂量萘普生来预防症状前AD进展。
- 临床决策时需权衡萘普生增加不良事件的风险。
局限性
- 改良意向性分析仅纳入160名至第一次随访仍在治疗的参与者。
- CSF生物标志物评估仅在约50%参与者中进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk. METHODS: Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS). RESULTS: Naproxen-treated individuals showed a clear excess of adverse events. Among treatment groups combined, the APS increased by 0.102 points/year (SE 0.014; p < 10-12), but rate of change showed little difference by treatment assignment (0.019 points/year). The treatment-related rate ratio of 1.16 (95% confidence interval 0.64-1.96) suggested that naproxen does not reduce the rate of APS progression by more than 36%. Secondary analyses revealed no notable treatment effects on individual CSF, cognitive, or neurosensory biomarker indicators of progressive presymptomatic AD. CONCLUSIONS: In cognitively intact individuals at risk, sustained treatment with naproxen sodium 220 mg twice daily increases frequency of adverse health effects but does not reduce apparent progression of presymptomatic AD. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that, for people who are cognitively intact, low-dose naproxen does not significantly reduce progression of a composite indicator of presymptomatic AD.
引用
- Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology. 2019. PMID: 30952794. doi:10.1212/WNL.0000000000007232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。